OriGene Technologies, Inc.
9620 Medical Center Drive, Ste 200
Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

Product datasheet for RC223935L4V

Kallikrein 2 (KLK2) (NM_001002231) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type:	Lentiviral Particles
Product Name:	Kallikrein 2 (KLK2) (NM_001002231) Human Tagged ORF Clone Lentiviral Particle
Symbol:	KLK2
Synonyms:	hGK-1; hK2; KLK2A2
Mammalian Cell Selection:	Puromycin
Vector:	pLenti-C-mGFP-P2A-Puro (PS100093)
Tag:	mGFP
ACCN:	NM_001002231
ORF Size:	669 bp
ORF Nucleotide Sequence:	The ORF insert of this clone is exactly the same as(RC223935).
OTI Disclaimer:	The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation:	This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
RefSeq:	NM_001002231.1
RefSeq Size:	2892 bp
RefSeq ORF:	672 bp
Locus ID:	3817
UniProt ID:	P20151
Cytogenetics:	19q13.33
Protein Families:	Druggable Genome, Protease
MW:	24.5 kDa

View online »

Gene Summary: This gene encodes a member of the grandular kallikrein protein family. Kallikreins are a subgroup of serine proteases that are clustered on chromosome 19. Members of this family are involved in a diverse array of biological functions. The protein encoded by this gene is a highly active trypsin-like serine protease that selectively cleaves at arginine residues. This protein is primarily expressed in prostatic tissue and is responsible for cleaving pro-prostate-specific antigen into its enzymatically active form. This gene is highly expressed in prostate tumor cells and may be a prognostic maker for prostate cancer risk. Alternate splicing results in both coding and non-coding transcript variants. [provided by RefSeq, Jan 2012]